{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:35:01Z","timestamp":1783038901063,"version":"3.54.6"},"reference-count":38,"publisher":"Frontline Medical Communications, Inc.","issue":"1","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Cutaneous Medicine and Surgery"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.sder.2010.01.001","type":"journal-article","created":{"date-parts":[[2010,4,28]],"date-time":"2010-04-28T13:17:13Z","timestamp":1272460633000},"page":"16-19","source":"Crossref","is-referenced-by-count":43,"title":["Assessing Long-Term Drug Safety: Lessons (Re) Learned from Raptiva"],"prefix":"10.12788","volume":"29","author":[{"given":"Nicole M.","family":"Seminara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Gelfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5043","reference":[{"key":"10.1016\/j.sder.2010.01.001_bib1","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.sder.2010.01.001_bib2","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1038\/jid.2009.112","article-title":"The risk of stroke in patients with psoriasis","volume":"129","author":"Gelfand","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.sder.2010.01.001_bib3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaad.2004.04.014","article-title":"Determinants of quality of life in patients with psoriasis: a study from the US population","volume":"51","author":"Gelfand","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2010.01.001_bib4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2005.03.046","article-title":"Epidemiology of psoriatic arthritis in the population of the United States","volume":"53","author":"Gelfand","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2010.01.001_bib5","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/archderm.143.12.1493","article-title":"The risk of mortality in patients with psoriasis: results from a population-based study","volume":"143","author":"Gelfand","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2010.01.001_bib6","unstructured":"Mehta NN, Azfar RS, Shin DB, et al: Patients with severe psoriasis are at increased risk of cardiovascular mortality: a cohort study using the general practice research database. Eur Heart J (in press)"},{"issue":"3 Pt. 1","key":"10.1016\/j.sder.2010.01.001_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2010.01.001_bib8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jaad.2008.09.022","article-title":"The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004","volume":"60","author":"Kurd","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2010.01.001_bib10","series-title":"Raptiva (efalizumab) [package insert]","year":"2009"},{"key":"10.1016\/j.sder.2010.01.001_bib12","series-title":"European Medicines Agency recommends suspension of the marketing authorisation of Raptiva (efalizumab)","year":"2009"},{"key":"10.1016\/j.sder.2010.01.001_bib14","series-title":"Pharmacoepidemiology","year":"2005"},{"key":"10.1016\/j.sder.2010.01.001_bib15","series-title":"Comprehensive Dermatologic Drug Therapy","article-title":"Pharmacovigilance: verifying that drugs remain safe","author":"Gelfand","year":"2004"},{"key":"10.1016\/j.sder.2010.01.001_bib16","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1517\/14656566.3.9.1289","article-title":"Adverse drug reactions: current issues and strategies for prevention and management","volume":"3","author":"Khong","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.sder.2010.01.001_bib17","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJMp058029","article-title":"Safety in numbers\u2014monitoring risk in approved drugs","volume":"352","author":"Okie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2010.01.001_bib18","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM198405033101805","article-title":"Cutaneous squamous-cell carcinoma in patients treated with PUVA","volume":"310","author":"Stern","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2010.01.001_bib19","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM199704103361501","article-title":"Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA)","volume":"336","author":"Stern","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2010.01.001_bib20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaad.2009.08.026","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5","volume":"62","author":"Menter","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2010.01.001_bib21","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2010.01.001_bib22","series-title":"FDA Drug Review: Postapproval risks 1976-85","year":"1990"},{"key":"10.1016\/j.sder.2010.01.001_bib23","series-title":"The importance of pharmacovigilance: safety monitoring of medicinal products","year":"2002"},{"key":"10.1016\/j.sder.2010.01.001_bib24","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1681\/ASN.2006060601","article-title":"Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging","volume":"17","author":"Marckmann","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"2 Pt. 1","key":"10.1016\/j.sder.2010.01.001_bib25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0190-9622(89)70176-6","article-title":"Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis","volume":"21","author":"Stern","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.sder.2010.01.001_bib26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.sder.2010.01.001_bib27","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bmj.38701.399942.63","article-title":"Case reports of suspected adverse drug reactions\u2014systematic literature survey of follow-up","volume":"332","author":"Loke","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.sder.2010.01.001_bib28","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMp0805922","article-title":"Drug warnings that can cause fits\u2014communicating risks in a data-poor environment","volume":"359","author":"Avorn","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2010.01.001_bib29","series-title":"FDA: Report on the performance of drug and biologics firms in conducting postmarketing commitment studies","year":"2004"},{"key":"10.1016\/j.sder.2010.01.001_bib30","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1056\/NEJMp078212","article-title":"Bolstering the FDA's drug-safety authority","volume":"357","author":"Schultz","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2010.01.001_bib31","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1001\/archdermatol.2009.188","article-title":"The misperception that clinical trial data reflect long-term drug safety: lessons learned from efalizumab's withdrawal","volume":"145","author":"Nijsten","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2010.01.001_bib32","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1001\/jama.290.23.3073","article-title":"Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial","volume":"290","author":"Gordon","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.sder.2010.01.001_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/archderm.141.1.31","article-title":"Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis","volume":"141","author":"Menter","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2010.01.001_bib34","series-title":"Important safety information","author":"Barron","year":"2008"},{"key":"10.1016\/j.sder.2010.01.001_bib35","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1212\/WNL.41.11.1733","article-title":"Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data","volume":"41","author":"Holman","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.sder.2010.01.001_bib36","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/archdermatol.2009.175","article-title":"Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists","volume":"145","author":"Korman","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.sder.2010.01.001_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.sder.2010.01.001_bib38","series-title":"FDA: Public health advisory\u2014suspended marketing of Tysabri (natalizumab)","year":"2005"},{"key":"10.1016\/j.sder.2010.01.001_bib39","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy","volume":"354","author":"Yousry","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.sder.2010.01.001_bib40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nbt0409-303","article-title":"RIP Raptiva?","volume":"27","author":"DeFrancesco","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.sder.2010.01.001_bib41","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archderm.143.9.1191","article-title":"Long-term treatment for severe psoriasis: we're halfway there, with a long way to go","volume":"143","author":"Gelfand","year":"2007","journal-title":"Arch Dermatol"}],"container-title":["Seminars in Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1085562910000088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1085562910000088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scmsjournal.com\/wp-content\/uploads\/2016\/01\/Vol29_i1-Long-Term-Drug-Safety.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T15:06:56Z","timestamp":1616166416000},"score":1,"resource":{"primary":{"URL":"http:\/\/scmsjournal.com\/article\/abstract\/assessing-long-term-drug-safety-lessons-re-learned-from-raptiva\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1085562910000088"],"URL":"https:\/\/doi.org\/10.1016\/j.sder.2010.01.001","relation":{},"ISSN":["1085-5629"],"issn-type":[{"value":"1085-5629","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}